Johnson & Johnson Announces New Data on RYBREVANT and LAZCLUZE Combination in NSCLC
ByAinvest
Saturday, Sep 6, 2025 3:04 am ET1min read
JNJ--
Johnson & Johnson announced new analyses from the Phase 3 MARIPOSA study showing that RYBREVANT plus LAZCLUZE significantly reduces EGFR- and MET-driven resistance compared to osimertinib in EGFR-mutated non-small cell lung cancer patients. The combination also extends survival and reduces common EGFR and MET resistance mutations. The data build on the combination's previously reported overall survival benefit and underscore its potential to change the biology of the disease by preventing acquired resistance.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet